Tag: 100-200

《Cation-Anion and Anion-CO2 Interactions in Triethyl(octyl)phosphonium Ionic Liquids with Aprotic Heterocyclic Anions (AHAs)》 was published in Journal of Physical Chemistry B in 2020. These research results belong to Oh, Seungmin; Morales-Collazo, Oscar; Keller, Austin N.; Brennecke, Joan F.. Quality Control of 3-(Trifluoromethyl)-1H-pyrazole The article mentions the following:

Ionic liquids with aprotic heterocyclic anions (AHAs) have been developed for postcombustion CO2 capture applications. The anions of AHA ILs play a significant role in tuning anion-CO2 complexation. In addition, AHAs are able to trigger the abstraction of acidic protons located at the α position of phosphonium cations by forming hydrogen bonds between cations and anions, eventually leading to cation-driven CO2 complexation. Here we investigate the role of the anion in cation-anion hydrogen bonding and ylide formation. Using CO2 uptake measurements, 31P NMR, attenuated total reflection-Fourier transform IR (ATR-FTIR), deuterium exchange equilibrium and rates, two-dimensional nuclear Overhauser effect spectroscopy (2D NOESY), and d. functional theory calculations, we show that the key is the proximity of the neg. charged nitrogen atoms on the anion to the α protons, which is governed not just by anion basicity but by sterics. Thus, we show that triethyl(octyl)phosphonium 3-methyl-5-trifluoromethylpyrazolide is much more effective in hydrogen-bonding with and deprotonating the cation than the equivalent [P2228] ILs with more basic 2-cyanopyrrolide and 3-trifluoromethylpyrazolide anions. In the part of experimental materials, we found many familiar compounds, such as 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Quality Control of 3-(Trifluoromethyl)-1H-pyrazole)

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Quality Control of 3-(Trifluoromethyl)-1H-pyrazole

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 2018,Liang, Yufan; Zhang, Xiaheng; MacMillan, David W. C. published 《Decarboxylative sp3 C-N coupling via dual copper and photoredox catalysis》.Nature (London, United Kingdom) published the findings.Recommanded Product: 3-(Trifluoromethyl)-1H-pyrazole The information in the text is summarized as follows:

Over the past three decades, considerable progress has been made in the development of methods to construct sp2 carbon-nitrogen (C-N) bonds using palladium, copper or nickel catalysis. However, the incorporation of alkyl substrates to form sp3 C-N bonds remains one of the major challenges in the field of cross-coupling chem. Here we demonstrate that the synergistic combination of copper catalysis and photoredox catalysis can provide a general platform from which to address this challenge. This cross-coupling system uses naturally abundant alkyl carboxylic acids and com. available nitrogen nucleophiles as coupling partners. It is applicable to a wide variety of primary, secondary and tertiary alkyl carboxylic acids (through iodonium activation), as well as a vast array of nitrogen nucleophiles: nitrogen heterocycles, amides, sulfonamides and anilines can undergo C-N coupling to provide N-alkyl products in good to excellent efficiency, at room temperature and on short timescales (five minutes to one hour). We demonstrate that this C-N coupling protocol proceeds with high regioselectivity using substrates that contain several amine groups, and can also be applied to complex drug mols., enabling the rapid construction of mol. complexity and the late-stage functionalization of bioactive pharmaceuticals. In the experimental materials used by the author, we found 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Recommanded Product: 3-(Trifluoromethyl)-1H-pyrazole)

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Recommanded Product: 3-(Trifluoromethyl)-1H-pyrazole

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 2012,Chandrasekhar, Vadapalli; Nagarajan, Loganathan; Hossain, Sakiat; Gopal, Kandasamy; Ghosh, Surajit; Verma, Sandeep published 《Multicomponent Assembly of Anionic and Neutral Decanuclear Copper(II) Phosphonate Cages》.Inorganic Chemistry published the findings.HPLC of Formula: 20154-03-4 The information in the text is summarized as follows:

A multicomponent synthetic strategy involving Cu(II) ions, tert-butylphosphonic acid (t-BuPO3H2) and 3-substituted pyrazole ligands was adopted for the synthesis of soluble mol. Cu(II) phosphonates. The use of six different 3-substituted pyrazoles, 3-R-PzH [R = H, Me, CF3, Ph, 2-pyridyl (2-Py), and 2-methoxyphenyl (2-MeO-C6H4)] as ancillary ligands afforded nine different decanuclear cages, [Cu5(μ3-OH)2(O3P-t-Bu)3(3-R-Pz)2(X)2]2·(Y) where R = H, X = t-BuPO3H, and Y = (Et3NH+)4(solvent) (1); R = Me, X = 3-MePzH, and Y = solvent (2); R = Me, X = t-BuPO3H, and Y = (Et3NH+)4(solvent) (3); R = CF3, X = t-BuPO3H, and Y = (Et3NH+)4(solvent) (4); R = Ph, X = 3-PhPzH, and Y = solvent (5); R = 2-Py, X = 0.5 MeOH, and Y = solvent (6); R = 2-Py, X = none, and Y = solvent (7); R = 2-Py, X = H2O, and Y = (Et3NH+·PF6-)2(solvent) (8); R = 2-MeO-C6H4, X = MeOH or 0.5:0.5 MeOH/H2O, and Y = solvent (9). Compounds 1-6, 8, and 9 were isolated using a direct synthetic method which involves the reaction of Cu(II) salts and the ligands, while 7 was obtained from an indirect route involving the reaction of preformed Cu-pyridylpyrazolate precursor complexes and t-BuPO3H2. The decametallic compounds 1-9 possess a butterfly-shaped core. The core of the cages 1, 3, and 4 are tetraanionic and contain more phosphonates than pyrazole ligands, while the other cages are neutral and contain more pyrazoles than phosphonate ligands. Compounds 1-6 were studied by electrospray ionization-high-resolution mass spectrometry (ESI-HRMS). The decanuclear cage 6 is a good plasmid modifier. The experimental part of the paper was very detailed, including the reaction process of 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4HPLC of Formula: 20154-03-4)

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.HPLC of Formula: 20154-03-4

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 2011,Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P. published 《Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)》.Journal of Medicinal Chemistry published the findings.Synthetic Route of C9H15BN2O2 The information in the text is summarized as follows:

Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention. The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design. A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3. In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE). Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties. The experimental part of the paper was very detailed, including the reaction process of 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 844501-71-9Synthetic Route of C9H15BN2O2)

3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 844501-71-9) belongs to pyrazoles. Pyrazoles are commonly used scaffold molecules in drug discovery projects. The use of pyrazole derivatives is based on their analgesic, antipyretic, neuroleptic, anticonvulsant, antiarrhythmic, sedative, muscle relaxant, monoamine oxidase inhibitory, anti-inflammatory, antidiabetic and antibacterial activities. Synthetic Route of C9H15BN2O2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 1960,Gundermann, Karl Dietrich; Thomas, Rainer published 《Mercaptoacrylic acid derivatives. VII. The effect of thioether groups on the stabilization of 1-pyrazoline-3-carboxylic acid derivatives》.Chemische Berichte published the findings.Product Details of 15366-34-4 The information in the text is summarized as follows:

cf. CA 54, 289b. 3-Alkylthio-1-pyrazoline-3-carboxylic acid esters, readily obtained from α-alkylthioacrylic acid esters and CH2N2, split off mercaptans at room temperature to yield pyrazole-3-carboxylic acid esters, but N at 50° to give mixtures of 1-alkylthiocyclopropane-1-carboxylic acid esters and α-alkylthiocrotonic acid esters. Pyrazoline derivs, from α-alkylthioacrylonitriles and CH2N2 underwent only a stabilization reaction with the elimination of N. CH2:C(SMe)CO2Me (21.4 g.) in 200 cc. Et2O treated with CH2N2 from 25 g. H2NCON(NO)Me (I) in 200 cc. Et2O, kept overnight, filtered, evaporated in vacuo at 30°, the resulting light yellow, oily pyrazoline derivative added dropwise to a flask preheated to 90-100°, heated about 0.5 hr. on the steam bath, and fractionated gave 19.8 g. 3:1 mixture of the Me ester (II) of 1-methylthiocyclopropane-1-carboxylic acid (III) and Me α-(methylthio)crotonate (IV), b15 70-82°, n20D 1.4835. (III-IV mixture (15 g.) and 50 cc. 20% HCl refluxed about 6 hrs., evaporated in vacuo, and the residue (7.7 g.) recrystallized from 20% HCl gave III, m. 65-6°, b0.2 84-6°, Rf 0.90 (4:1:5 BuOH-glacial AcOH-H2O), colorless prisms; III with CH2N2 gave 100% pure II, b14 74°, n20D 1.4823. II treated room temperature with concentrated NH4OH and evaporated yielded the amide of III, prisms, m. 89° (petr. ether). Crude pyrazoline derivative from CH2:C(SMe)CO2Me and CH2N2 kept 1 week at room temperature and filtered gave the Me ester of pyrazole-3-carboxylic acid (V), m. 140° (aqueous MeOH), which was saponified to V, m. 212°. II-III mixture (3 g.) treated about 24 hrs. at room temperature with liquid NH3 gave 0.6 g. MeCH(NH2)-CH(SMe)CO2H, Rf 0.64; saponification of the nonbasic portion of the product gave 1.7 g. III. Me3CSH (45 g.) added dropwise with stirring to 60 g. CH2:CClCO2Me and 2.3 g. NaOMe at 45-50°, kept overnight, diluted with Et2O, washed, dried, and fractionated gave 68.7 g. Me3CSCH2CHClCO2Me (VI), b0.4 85-6°, b0.2 77-8°, n20D 1.4790. VI (42 g.), 26.2 g. powd. KBr, 22.2 g. Et3N, and 170 cc. HCONMe2 gave in the usual manner 22.8 g. Me2CSC(:CH2)CO2Me (VII), b12 92-3°. n20D 1.4795. VII (8.6 g.) in 70 cc. Et2O treated with CH2N2 from 10 g. I in 100 cc. Et2O, the product decomposed at 85-90°, and fractionated gave 7.0 g. oil, b12 83-5°, n20D 1.4803; the oil refluxed 1 hr. on the steam bath with 2 volumes 20% aqueous NaOH and 1 volume MeOH, filtered, acidified, and the product isolated with Et2O gave 3.8 g. 1-tert-butylthiocyclopropane-1-carboxylic acid, b0.2 93-4°, n22D 1.4955. The crude product from VII and CH2N2 kept 8 days at room temperature yielded 90% Me ester of V. CH2:C(SMe)CN (8 g.) in 80 cc. Et2O treated with CH2N2 from 12 g. I, the crude product dropped at 80-90° into a flask, and the residue fractionated yielded 6.85 g. 4:1 mixture of the nitrile of III and MeCH:C(SMe)CN, b11 67-9°, n20D 1.4900; the mixture heated 4 hrs. with a 5-fold amount 1:1 glacial AcOH-HCl, evaporated, the residue extracted with Me2CO, and the extract worked up gave 60% III. CH2:C(SCH2Ph)CN (11.5 g.) and CH2N2 from 11 g. I yielded similarly 10.53 g. 4:1 mixture of 1-benzylthio-1-cyanocyclopropane and MeCH:C(SCH2Ph)CN, b0.15 104-6°, n20D 1.5676; a 10-g. portion in 100 g. AcOH-HCl heated 7 hrs. on the steam bath and evaporated, the residue treated with Et2O and aqueous NaHCO3, and the aqueous phase acidified gave 5.55 g. 1-benzylthiocyclopropane-1-carboxylic acid, prisms, m. 132-3° (C6H6-petr. ether). MeCH:C(SMe)CO2Me (10 g.) in 100 cc. Et2O treated with CH2N2 from 10 g. I in 100 cc. Et2O, 1 g. of the resulting crude pyrazoline ester kept at room temperature, and filtered gave 0.51 g. Me 4-methylpyrazole-3-carboxylate (VIII), m. 172° (aqueous MeOH). Crude pyrazoline ester (12 g.) added dropwise to a flask at 110-13° gave 5.5 g. VIII, m. 172°; the residue from the petr. ether washings gave 2.65 g. unidentified oil, b15 88-91°, n20D 1.4902, which by acid hydrolysis gave MeSH. In the experiment, the researchers used many compounds, for example, Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4Product Details of 15366-34-4)

Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Product Details of 15366-34-4

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 2011,Organic & Biomolecular Chemistry included an article by Koos, Peter; Gross, Ulrike; Polyzos, Anastasios; O’Brien, Matthew; Baxendale, Ian; Ley, Steven V.. Related Products of 5952-93-2. The article was titled 《Teflon AF-2400 mediated gas-liquid contact in continuous flow methoxycarbonylations and in-line FTIR measurement of CO concentration》. The information in the text is summarized as follows:

We report on the development of a continuous flow process for the palladium catalyzed methoxycarbonylation of aryl, heteroaromatic and vinyl iodides and an aryl bromide using a Teflon AF-2400 based Tube-in-Tube reactor to mediate the selective permeation of carbon monoxide into solution at elevated pressures. The low volume of pressurized gas within the reactor (5.6 mL) offers the potential for an enhanced safety profile compared to batch processes. We also present preliminary results for the use of in situ FTIR to measure solution concentrations of carbon monoxide and demonstrate the use of a second reactor to effect the removal of carbon monoxide from the flow stream. After reading the article, we found that the author used Methyl 1-methyl-1H-pyrazole-4-carboxylate(cas: 5952-93-2Related Products of 5952-93-2)

Methyl 1-methyl-1H-pyrazole-4-carboxylate(cas: 5952-93-2) belongs to pyrazoles. Pyrazoles and their related multiring analogs are common elements of a wide variety of bioactive compounds. These ring structures are rare in nature. A consequence of this is that they have previously been thought to be poor moieties to include in potential new drugs. Related Products of 5952-93-2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 1972,Acta Pharmaceutica Suecica included an article by Carlson, Lars A.; Hedbom, Christina; Helgstrand, Erik; Sjoberg, Berndt; Stjernstrom, Nils E.. Synthetic Route of C5H8N2O. The article was titled 《Potential hypolipidemic agents. III. Heterocyclic compounds affecting free fatty acid mobilization in vivo》. The information in the text is summarized as follows:

Compounds such as 3-methyl-5-isoxazolecarboxylic acid [4857-42-5], 5-fluoronicotinic acid [402-66-4], 5-fluoro-3-pyridylacetic acid [38129-24-7], and 3-methylpyrazole [1453-58-3] exhibited the highest inhibition of free fatty acid mobilization in blood among 188 heterocyclic compounds tested in dogs, while compounds such as 5-methyl-3-isoxazolecarboxylic acid [3405-77-4], 2-fluoronicotinic acid [393-55-5], and 3-aminobenzoic acid [99-05-8] had no effect on free fatty acid mobilization. In the experiment, the researchers used (3-methyl-1H-pyrazol-5-yl)methanol(cas: 29004-73-7Synthetic Route of C5H8N2O)

(3-methyl-1H-pyrazol-5-yl)methanol(cas: 29004-73-7) belongs to pyrazoles. Pyrazoles and their related multiring analogs are common elements of a wide variety of bioactive compounds. These ring structures are rare in nature. A consequence of this is that they have previously been thought to be poor moieties to include in potential new drugs. Synthetic Route of C5H8N2O

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Recommanded Product: 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazoleIn 2015 ,《Discovery of potent and selective urea-based ROCK inhibitors: Exploring the inhibitor’s potency and ROCK2/PKA selectivity by 3D-QSAR, molecular docking and molecular dynamics simulations》 appeared in Bioorganic & Medicinal Chemistry. The author of the article were Mei, Ding; Yin, Yan; Wu, Fanhong; Cui, Jiaxing; Zhou, Hong; Sun, Guofeng; Jiang, Yu; Feng, Yangbo. The article conveys some information:

An activity model and a selectivity model from 3D-QSAR studies were established by CoMFA and CoMSIA to explore the SAR. Then docking was used to study the binding modes between ligand and kinases (ROCK2 and PKA), and the mol. docking results were further validated by MD simulations. Computational results suggested that substitution containing pos. charge attached to the middle Ph ring, or electropos. group in urea linker was favored for both activity and ROCK2/PKA selectivity. Finally, three compounds were designed, and biol. evaluation demonstrated that these mol. models were effective for guiding the design of potent and selective ROCK inhibitors. The results came from multiple reactions, including the reaction of 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 844501-71-9Recommanded Product: 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole)

3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 844501-71-9) belongs to pyrazoles. Pyrazoles are commonly used scaffold molecules in drug discovery projects. The use of pyrazole derivatives is based on their analgesic, anti-inflammatory, antipyretic, antiarrhythmic, sedative, muscle relaxant, neuroleptic, anticonvulsant, monoamine oxidase inhibitory, antidiabetic and antibacterial activities. Recommanded Product: 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Related Products of 20154-03-4In 2017 ,《Antimicrobial activities of pyridinium-tailored pyrazoles bearing 1,3,4-oxadiazole scaffolds》 appeared in Journal of Saudi Chemical Society. The author of the article were Zhou, Lei; Wang, Pei-Yi; Zhou, Jian; Shao, Wu-Bin; Fang, He-Shu; Wu, Zhi-Bing; Yang, Song. The article conveys some information:

Herein, a series of pyridinium-tailored 5-trifluoromethylpyrazoles containing 1,3,4-oxadiazole moieties were constructed through coupling key pharmaceutical fragments of pyridinium, pyrazole, and 1,3,4-oxadiazole scaffolds in single mol. architecture. Antimicrobial results suggested that this kind of compounds exhibited significant activities against three types of pathogenic bacteria and six fungal strains in vitro. The minimal EC50 values of designed compounds against Xanthomonas oryzae pv. oryzae, Ralstonia solanacearum, and Xanthomonas axonopodis pv. citri could reach to 0.467, 1.04, and 0.600μg/mL, resp., through tuning and optimizing N-substituents, bridging atom, and alkyl length of the tailor. Antifungal assays revealed that all title mols. possessed considerable activity against Botrytis cinerea with the minimal EC50 value up to 2.71μg/mL; and compounds I-8, I-10, I-12, II-12, and IV-12 showed the strongest growth suppression toward Rhizoctonia solani with EC50 values ranging from 10.2 to 24.0μg/mL. Given the above results, this kind of compounds could serve as new lead compounds in the research of antimicrobial chemotherapy. The results came from multiple reactions, including the reaction of 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Related Products of 20154-03-4)

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. Pyrazole derivatives have been reported to exhibit a wide range of applications in medicinal chemistry and pharmacology. A large number of drugs incorporating pyrazole structure have been utilized as partial agonists for nicotinic acid receptors, antidepressants, antimicrobial agents, antiviral agents, and antifungal agents solely or along with the combination of other structural motifs.Related Products of 20154-03-4

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Che, Jinxin; Dai, Xiaoyang; Gao, Jian; Sheng, Haichao; Zhan, Wenhu; Lu, Yang; Li, Dan; Gao, Zizheng; Jin, Zegao; Chen, Binhui; Luo, Peihua; Yang, Bo; Hu, Yongzhou; He, Qiaojun; Weng, Qinjie; Dong, Xiaowu published their research in Journal of Medicinal Chemistry in 2021. The article was titled 《Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity》.Electric Literature of C9H15BN2O2 The article contains the following contents:

Here, the inhibition of Akt2 isoenzyme might be a driver for keratinocyte apoptosis was demonstrate, which promotes us to search for new selective Akt inhibitor compounds I [R1 = 4-F, 3,4-di-F, 3,5-di-F; R2 = 2-F, 3-F, 2-Cl, 2,6-di-F, 2,5-di-F, 2-F-6-Cl; R3 = H, Cl, Br; R4 = H, Me, Et] with an improved cutaneous safety property. According to our previous research, compound I [R1 = 3,4-di-F; R2 = R3 = H; R4 = Me] was selected for further optimization for overcoming the disadvantages of compound II, including high Akt2 inhibition and high toxicity against HaCaT keratinocytes. The dihedral angle-based design and mol. dynamics simulation led to the identification of Hu7691 I [R1 = 3,4-di-F; R2 = 2-F; R3 = H; R4 = Me] that achieves a 24-fold selectivity between Akt1 and Akt2. Hu7691 I [R1 = 3,4-di-F; R2 = 2-F; R3 = H; R4 = Me] exhibited low activity in inducing HaCaT apoptosis, promising kinase selectivity, and excellent anticancer cell proliferation potencies. Based on the superior results of safety property, pharmacokinetic profile, and in vivo efficacy, the National Medical Products Administration (NMPA) approved the investigational new drug (IND) application of Hu7691 I [R1 = 3,4-di-F; R2 = 2-F; R3 = H; R4 = Me]. In the part of experimental materials, we found many familiar compounds, such as 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 844501-71-9Electric Literature of C9H15BN2O2)

3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 844501-71-9) belongs to pyrazoles. Pyrazoles are commonly used scaffold molecules in drug discovery projects. The use of pyrazole derivatives is based on their analgesic, anti-inflammatory, antipyretic, antiarrhythmic, sedative, muscle relaxant, neuroleptic, anticonvulsant, monoamine oxidase inhibitory, antidiabetic and antibacterial activities. Electric Literature of C9H15BN2O2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics